STAT Plus: Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst
MICHELLE MONJE/STANFORD UNIVERSITY/NIH
Tocagen's Phase 3 clinical trial of a gene therapy for aggressive brain tumors will continue to a final analysis, a decision that will be debated.
No hay comentarios:
Publicar un comentario